Akston's NGF-Targeting Ambifect® Candidates Demonstrate Clinically Meaningful Osteoarthritis Pain and Function Improvements Comparable to Bedinvetmab in Head-to-Head Canine Study

ConferencepositiveAKS-548dAKS-734Ambifect®Positive

AI Analysis

Summary

Akston's NGF-targeting candidates AKS-548d and AKS-734 demonstrated clinically meaningful improvements in osteoarthritis pain and function comparable to Bedinvetmab in a head-to-head canine study presented at ACVIM 2026 Forum.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

AKS-548d and AKS-734 demonstrated sustained anti-NGF antibody responses, functional neutralization of NGF binding to TrkA, and clinically meaningful reductions in canine osteoarthritis pain comparable to Bedinvetmab in head-to-head study

Importance:5/10

Sentiment:

0.75

NGF inhibitorosteoarthritiscanine studyantibodyconference presentation

Related Companies

$MEHA $ATALF $SHWZ

Read the original article

Published by PR Newswire Biotech on July 7, 2026 1:30 PM

Read Original